Collaboration comes amidst reports that the Trump administration is exploring cannabis rescheduling, expected to create unprecedented opportunities in the U.S. for international operators like ...
InterCure will also have the right to use the name, the marks and the TYSON 2.0 intellectual property in the said territories. Announced a voluntary delisting of our ordinary shares from the Toronto ...
Revenues during the first half of 2024 reached NIS 126 million, alongside an Adjusted EBITDA 1 of NIS 21 million (Approximately 17% of revenues). Alexander Rabinovitch, CEO of InterCure noted: ...
The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive ...
NEW YORK and HERZLIYA, Israel, Oct. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results